News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
TMX Newsfile
NEWS
IN THE PRESS
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Update
August 19, 2025
·
2 min read
Press Releases
Hemostemix Announces Its AI Strategy
August 19, 2025
·
8 min read
Press Releases
OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
August 19, 2025
·
10 min read
Press Releases
BioGene Therapeutics Inc. Appoints Dr. Kamal Albarazanji as Senior Director of Metabolic Research
August 19, 2025
·
6 min read
Press Releases
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
August 18, 2025
·
4 min read
Press Releases
Maxwell Biosciences Marks Scientist Appreciation Day With Renewed Call to Recognize Scientists
August 18, 2025
·
2 min read
Press Releases
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
August 14, 2025
·
3 min read
Press Releases
Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
·
8 min read
Press Releases
Hemostemix’s Expands its Marketing Team Focused on Sales in Florida
August 14, 2025
·
9 min read
Press Releases
PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))
August 14, 2025
·
6 min read
15 Toronto St., Suite 601 Toronto ON M5C 2E3 US
Tel: 416-806-1750
Visit website
Email Us